Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H23N3O2 |
Molecular Weight | 349.4262 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C(N1)C=CC=C3
InChI
InChIKey=FPOHNWQLNRZRFC-ZHACJKMWSA-N
InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+
Molecular Formula | C21H23N3O2 |
Molecular Weight | 349.4262 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.drugbank.ca/drugs/DB06603
Curator's Comment: Description was created based on several sources, including
https://www.drugbank.ca/drugs/DB06603
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat is a deacetylase (DAC) inhibitor. DACs, also known as histone DACs (HDAC), are responsible for regulating the acetylation of about 1750 proteins in the body; their functions are involved in many biological processes including DNA replication and repair, chromatin remodelling, transcription of genes, progression of the cell-cycle, protein degradation and cytoskeletal reorganization. In multiple myeloma, there is an overexpression of DAC proteins. Panobinostat inhibits class I (HDACs 1, 2, 3, 8), class II (HDACs 4, 5, 6, 7, 9, 10) and class IV (HDAC 11) proteins. Panobinostat's antitumor activity is believed to be attributed to epigenetic modulation of gene expression and inhibition of protein metabolism. Panobinostat also exhibits cytotoxic synergy with bortezomib, a proteasome inhibitor concurrently used in treatment of multiple myeloma.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800020423
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3192 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22344701 |
280.0 nM [IC50] | ||
Target ID: CHEMBL1865 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22344701 |
11.0 nM [IC50] | ||
Target ID: CHEMBL1829 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22344701 |
2.1 nM [IC50] | ||
Target ID: CHEMBL1937 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22344701 |
13.0 nM [IC50] | ||
Target ID: CHEMBL325 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22344701 |
2.5 nM [IC50] | ||
Target ID: CHEMBL3524 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22344701 |
200.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FARYDAK Approved UseFARYDAK, a histone deacetylase inhibitor, in combination with bortezomib
and dexamethasone, is indicated for the treatment of patients with multiple
myeloma who have received at least 2 prior regimens, including bortezomib
and an immunomodulatory agent Launch Date2015 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15.3 ng/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: BORTEZOMIB |
PANOBINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95.2 ng × h/mL |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: BORTEZOMIB |
PANOBINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.7 h |
20 mg 1 times / day multiple, oral dose: 20 mg route of administration: Oral experiment type: MULTIPLE co-administered: BORTEZOMIB |
PANOBINOSTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
PANOBINOSTAT plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
34 mg/m2 3 times / week multiple, oral Highest studied dose|RP2D Dose: 34 mg/m2, 3 times / week Route: oral Route: multiple Dose: 34 mg/m2, 3 times / week Sources: |
unhealthy, 1-21 years n = 11 Health Status: unhealthy Condition: relapsed and refractory hematologic malignancies Age Group: 1-21 years Sex: M+F Population Size: 11 Sources: |
DLT: Hypertriglyceridemia... Dose limiting toxicities: Hypertriglyceridemia (grade 4, 1 patient) Sources: |
15 mg/m2 1 times / week multiple, intravenous (starting) Dose: 15 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 15 mg/m2, 1 times / week Sources: |
unhealthy, 3-17 years n = 9 Health Status: unhealthy Condition: refractory solid tumors Age Group: 3-17 years Sex: M+F Population Size: 9 Sources: |
DLT: Electrocardiogram T wave abnormal... Dose limiting toxicities: Electrocardiogram T wave abnormal (2 patients) Sources: |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Disc. AE: Diarrhea, Thrombocytopenia... AEs leading to discontinuation/dose reduction: Diarrhea (17 patients) Sources: Page: p. 36, 45Thrombocytopenia (6 patients) Fatigue (11 patient) Asthenia (11 patient) Peripheral neuropathy (14 patients) Thrombocytopenia (28%) |
20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
DLT: Gamma glutamyl transpeptidase increased... Other AEs: Thrombocytopenia, Leukopenia... Dose limiting toxicities: Gamma glutamyl transpeptidase increased (grade 3, 1 patient) Other AEs:Thrombocytopenia (grade 3-4, 2 patients) Sources: Leukopenia (grade 3-4, 2 patients) Neutropenia (grade 3-4, 5 patients) Nausea (grade 1-2, 4 patients) Stomatitis (grade 1-2, 3 patients) Vomiting (grade 1-2, 3 patients) Fatigue (grade 3-4, 1 patient) Fever (grade 1-2, 4 patients) Decreased appetite (grade 1-2, 5 patients) Hypoalbuminemia (grade 1-2, 2 patients) Rash (grade 1-2, 3 patients) |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Other AEs: Diarrhea, Arrhythmia... Other AEs: Diarrhea (severe|grade 5, 25%) Sources: Arrhythmia (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypertriglyceridemia | grade 4, 1 patient DLT |
34 mg/m2 3 times / week multiple, oral Highest studied dose|RP2D Dose: 34 mg/m2, 3 times / week Route: oral Route: multiple Dose: 34 mg/m2, 3 times / week Sources: |
unhealthy, 1-21 years n = 11 Health Status: unhealthy Condition: relapsed and refractory hematologic malignancies Age Group: 1-21 years Sex: M+F Population Size: 11 Sources: |
Electrocardiogram T wave abnormal | 2 patients DLT |
15 mg/m2 1 times / week multiple, intravenous (starting) Dose: 15 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 15 mg/m2, 1 times / week Sources: |
unhealthy, 3-17 years n = 9 Health Status: unhealthy Condition: refractory solid tumors Age Group: 3-17 years Sex: M+F Population Size: 9 Sources: |
Asthenia | 11 patient Disc. AE |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Fatigue | 11 patient Disc. AE |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Peripheral neuropathy | 14 patients Disc. AE |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Diarrhea | 17 patients Disc. AE |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Thrombocytopenia | 28% Disc. AE |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Thrombocytopenia | 6 patients Disc. AE |
20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Co-administed with:: bortezomib(1.3 mg/m2) Sources: Page: p. 36, 45dexamethasone |
unhealthy, 60 years (range: 28-79 years) n = 386 Health Status: unhealthy Age Group: 60 years (range: 28-79 years) Sex: M+F Population Size: 386 Sources: Page: p. 36, 45 |
Hypoalbuminemia | grade 1-2, 2 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Rash | grade 1-2, 3 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Stomatitis | grade 1-2, 3 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Vomiting | grade 1-2, 3 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Fever | grade 1-2, 4 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Nausea | grade 1-2, 4 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Decreased appetite | grade 1-2, 5 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Gamma glutamyl transpeptidase increased | grade 3, 1 patient DLT |
20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Fatigue | grade 3-4, 1 patient | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Leukopenia | grade 3-4, 2 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Thrombocytopenia | grade 3-4, 2 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Neutropenia | grade 3-4, 5 patients | 20 mg/m2 1 times / week multiple, intravenous Highest studied dose Dose: 20 mg/m2, 1 times / week Route: intravenous Route: multiple Dose: 20 mg/m2, 1 times / week Sources: |
unhealthy, 63.0 years (range: 43–75 years) n = 8 Health Status: unhealthy Condition: advanced solid tumors Age Group: 63.0 years (range: 43–75 years) Sex: M+F Population Size: 8 Sources: |
Arrhythmia | severe | 20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Diarrhea | severe|grade 5, 25% | 20 mg 3 times / week multiple, oral Recommended|MTD Dose: 20 mg, 3 times / week Route: oral Route: multiple Dose: 20 mg, 3 times / week Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000PharmR.pdf#page=13 Page: 13.0 |
||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205353Orig1s000PharmR.pdf#page=13 Page: 13.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. | 2008 Jan 15 |
|
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. | 2009 Mar 1 |
|
SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. | 2013 May 16 |
|
A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. | 2015 Sep |
Sample Use Guides
20 mg, taken orally once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, and 12) of Weeks 1 and 2 of each 21-day cycle for 8 cycles
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19671764
Besides, Panobinostat inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:02:01 GMT 2023
by
admin
on
Fri Dec 15 18:02:01 GMT 2023
|
Record UNII |
9647FM7Y3Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175588
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
291509
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
244407
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
WHO-VATC |
QL01XX42
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
705919
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
FDA ORPHAN DRUG |
376212
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
WHO-ATC |
L01XX42
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
EU-Orphan Drug |
EU/3/09/721
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
||
|
NCI_THESAURUS |
C1946
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C496932
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
DTXSID40193506
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
DB06603
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
404950-80-7
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
CHEMBL483254
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
PANOBINOSTAT
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
YY-135
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
85990
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
N0000182137
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | Cytochrome P450 2D6 Inhibitors [MoA] | ||
|
4682
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
6918837
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
9647FM7Y3Z
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
SUB31049
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
m8383
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000115952
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
C66948
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
9647FM7Y3Z
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
8805
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
7489
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | |||
|
1603350
Created by
admin on Fri Dec 15 18:02:01 GMT 2023 , Edited by admin on Fri Dec 15 18:02:01 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->WEAK INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
TARGET->WEAK INHIBITOR |
IC50
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
TARGET->WEAK INHIBITOR |
IC50
|
||
|
BINDER->LIGAND |
Panobinostat is approximately 90% bound to human plasma proteins in vitro and is independent of concentration.
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
TRANSPORTER -> INHIBITOR |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
IN VITRO
|
||
|
TARGET -> INHIBITOR |
A PAN HDAC INHIBITOR.
IC50
|
||
|
METABOLIC ENZYME -> INHIBITOR |
TIME-DEPENDENT INHIBITION
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
The fraction metabolized through CYP3A accounts for approximately 40% of the total hepatic panobinostat elimination.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
FECAL
|
||
|
METABOLITE INACTIVE -> PARENT |
FECAL; PLASMA; URINE
|
||
|
METABOLITE -> PARENT |
FECAL; PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC |
|
||
Tmax | PHARMACOKINETIC |
|
IN PATIENTS WITH ADVANCED CANCER |
|
||